Acinetobacter ursingii

(aka Acinetobacter sp. phenon 1)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Acinetobacter ursingii, (aka Acinetobacter sp. phenon 1), is a Gram-negative, non-spore-forming, strictly aerobic, non-motile, coccobacillus bacterium. It has been detected in at least 1 gut microbiome compilation study or metastudy. Acinetobacter ursingii is likely to be transient and not a long-term gut coloniser. (Nemec2001)



  • This organism has been recovered from human faeces (Dijkshoorn2005) and clinical sources (wound, blood, infection - CCUG). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. Can cause opportunistic infections, particularly in immunocompromised people. Likely to be transient and not a long-term gut commensal.
    • QUIRKS
  • Obligate aerobe; unlikely to be a gut coloniser.
    • GENERAL CHARACTERISTICS (Nemec2001);
    Character Response
  • 🌡
  • Temperature tolerance:
  • grows at 37℃; doesn't grow at 41℃;
  • ⥅
  • Substrates assimilated or utilised:
  • ethanol; aspartate; glutamate; acetate; adipate; azelate; citrate; glutarate; 4-hydroxybenzoate; DL-lactate; glutamine; D-malate;
  • ±
  • Strain-dependent substrate utilisation:
  • benzoate;
    • SPECIAL FEATURES
    Character Response
  • ✗
  • Haemolysis:
  • absent
    • RESPONSE TO ANTIBIOTICS (Koizumi2019);
    Class Active Resistant
  • Penicillins:
  • penicillin G;
  • Heterocycles:
  • chloramphenicol;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Gammaproteobacteria Order:  Pseudomonadales Family:  Moraxellaceae Genus:  Acinetobacter Alt. name:  Acinetobacter sp. phenon 1 Gram stain:  neg O2 Relation.:  strictly aerobic Spore:  No spore Motility:  Sessile Morphology:  Coccobacillus
    Health:  Unknown
    Source:  human faeces (Dijkshoorn2005) and clinical sources (wound, blood, infection - CCUG)
    Mid T(℃):  37(+)
    High T(℃):  41(neg)
    		Gelatin:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Glucose:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    L-Arabinose:  neg Glucose:  neg Ribose:  neg Ethanol:  + Gluconate:  neg β-Ala:  neg 4-Aminobutyrate:  neg Arg:  neg Asp:  + Glu:  + Histamine:  neg His:  neg Leu:  neg Orn:  neg Phe:  neg Trigonelline:  neg Acetate:  + Aconitate:  trans(neg) Adipate:  + Azelate:  + Benzoate:  d Citraconate:  neg Citrate:  + Glutarate:  + 4-Hydroxybenzoate:  + DL-Lactate:  + Levulinate:  neg Malonate:  neg Phenylacetate:  neg L-Tartrate:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    penicillin_G:  Res
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    chloramphenicol:  Res

    References

    SPECIFIC REFERENCES FOR ACINETOBACTER URSINGII
  • Dijkshoorn2005 - Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals.
  • Koizumi2019 - The clinical characteristics of Acinetobacter bacteremia differ among genomospecies: A hospital-based retrospective comparative analysis of genotypically identified strains.
  • Nemec2001 - Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR ACINETOBACTER URSINGII
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • ...............................
    • Added: November 03, 2021